Circumstances, causes and timing of death in extremely preterm infants admitted to NICU: The EPIPAGE-2 study.

cause of death end of life decision extremely preterm infants preterm birth withdrawal

Journal

Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968

Informations de publication

Date de publication:
10 2023
Historique:
revised: 10 05 2023
received: 08 02 2023
accepted: 28 06 2023
medline: 11 9 2023
pubmed: 4 7 2023
entrez: 4 7 2023
Statut: ppublish

Résumé

To describe the circumstances, causes and timing of death in extremely preterm infants. We included from the EPIPAGE-2 study infants born at 24-26 weeks in 2011 admitted to neonatal intensive care units (NICU). Vital status and circumstances of death were used to define three groups of infants: alive at discharge, death with or without withholding or withdrawing life-sustaining treatment (WWLST). The main cause of death was classified as respiratory disease, necrotizing enterocolitis, infection, central nervous system (CNS) injury, other or unknown. Among 768 infants admitted to NICU, 224 died among which 89 died without WWLST and 135 with WWLST. The main causes of death were respiratory disease (38%), CNS injury (30%) and infection (12%). Among the infants who died with WWLST, CNS injury was the main cause of death (47%), whereas respiratory disease (56%) and infection (20%) were the main causes in case of death without WWLST. Half (51%) of all deaths occurred within the first 7 days of life, and 35% occurred within 8 and 28 days. The death of extremely preterm infants in NICU is a complex phenomenon in which the circumstances and causes of death are intertwined.

Identifiants

pubmed: 37402152
doi: 10.1111/apa.16894
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2066-2074

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-11-EQPX-0038
Organisme : Agence Nationale de la Recherche
ID : ANR-19-COHO-001
Organisme : Fondation de France
ID : 11779
Organisme : Fondation pour la Recherche Médicale
ID : SPF20160936356
Organisme : Fondation PremUP
Organisme : French Institute of Public Health Research
Organisme : programme hospitalier de recherche clinique
ID : Epinutri (DGOS13-040

Informations de copyright

© 2023 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Références

Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, et al. ELBW and ELGAN outcomes in developing nations-systematic review and meta-analysis. PLoS One. 2021;16:e0255352.
Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ. 2012;345:e7976.
Itabashi K, Horiuchi T, Kusuda S, et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics. 2009;123:445-450.
Ancel PY, Goffinet F, Kuhn P, et al. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr. 2015;169:230-238.
Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314:1039-1051.
van Beek PE, Groenendaal F, Broeders L, et al. Survival and causes of death in extremely preterm infants in The Netherlands. Arch Dis Child Fetal Neonatal Ed. 2021;106:251-257.
Perlbarg J, Ancel PY, Khoshnood B, et al. Delivery room management of extremely preterm infants: the EPIPAGE-2 study. Arch Dis Child Fetal Neonatal Ed. 2016;101:F384-F390.
Patel RM, Kandefer S, Walsh MC, et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med. 2015;372:331-340.
Patel RM. Short- and long-term outcomes for extremely preterm infants. Am J Perinatol. 2016;33:318-328.
Ancel PY, Goffinet F, EPIPAGE 2 Writing Group. EPIPAGE 2: a preterm birth cohort in France in 2011. BMC Pediatr. 2014;14:97.
Lorthe E, Benhammou V, Marchand-Martin L, et al. Cohort profile: the Etude Epidémiologique sur les Petits Ages Gestationnels-2 (EPIPAGE-2) preterm birth cohort. Int J Epidemiol. 2021;50:1428-1429. doi:10.1093/ije/dyaa282
Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1-7.
Chevallier M, Debillon T, Pierrat V, et al. Leading causes of preterm delivery as risk factors for intraventricular hemorrhage in very preterm infants: results of the EPIPAGE 2 cohort study. Am J Obstet Gynecol. 2017;216:518.e1-518.e12.
Delorme P, Goffinet F, Ancel P-Y, et al. Cause of preterm birth as a prognostic factor for mortality. Obstet Gynecol. 2016;127:40-48.
Rysavy MA, Li L, Bell EF, et al. Between-hospital variation in treatment and outcomes in extremely preterm infants. N Engl J Med. 2015;372:1801-1811.
Zegers MJ, Hukkelhoven CWPM, Uiterwaal CSPM, Kollée LAA, Groenendaal F. Changing Dutch approach and trends in short-term outcome of periviable preterms. Arch Dis Child Fetal Neonatal Ed. 2016;101:F391-F396.
Vieira MEB, Linhares MBM. Quality of life of individuals born preterm: a systematic review of assessment approaches. Qual Life Res. 2016;25:2123-2139.
Helenius K, Morisaki N, Kusuda S, et al. Survey shows marked variations in approaches to redirection of care for critically ill very preterm infants in 11 countries. Acta Paediatr. 2020;109:1338-1345.
Serenius F, Källén K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA. 2013;309:1810-1820.
Pierrat V, Marchand-Martin L, Arnaud C, et al. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study. BMJ. 2017;358:j3448.
Barfield WD, COMMITTEE ON FETUS AND NEWBORN. Standard terminology for fetal, infant, and perinatal deaths. Pediatrics. 2016;137:e20160551.

Auteurs

Pascal Boileau (P)

Department of Neonatal Pediatrics, Poissy Saint Germain Hospital, Versailles Saint Quentin en Yvelines University, Poissy, France.

Mathilde Letouzey (M)

Department of Neonatal Pediatrics, Poissy Saint Germain Hospital, Versailles Saint Quentin en Yvelines University, Poissy, France.
Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.

Andrei S Morgan (AS)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Department of Neonatology, North Hospital, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Elizabeth Garrett Anderson Institute for Women's Health London, University College London, London, UK.

Elsa Lorthe (E)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Unit of Population Epidemiology, Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.

Monique Kaminski (M)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.

Anaëlle Coquelin (A)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.

Elie Azria (E)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Department of Obstetrics, Saint-Joseph Hospital, Paris, France.

Laurence Caeymaex (L)

Department of Neonatal Pediatrics and Intensive Care, CHI, CRC, Créteil, France.

Florence Rouget (F)

Department of Neonatal Pediatrics, University Hospital Rennes, Rennes, France.

Caroline Diguisto (C)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Department of Gynecology and Obstetrics, University hospital Tours, Tours, France.

Olivier Claris (O)

Hospices Civils de Lyon, Department of Neonatology, Claude Bernard University, Lyon, France.

Barthélémy Tosello (B)

Department of Neonatology, North Hospital, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Aix-Marseille Univ, CNRS, EFS, ADES, Marseille, France.

Patrick Truffert (P)

Department of Neonatal Medicine, Jeanne de Flandre Hospital, CHRU Lille, Lille, France.

Pierre Bétrémieux (P)

Department of Neonatal Pediatrics, University Hospital Rennes, Rennes, France.

Valérie Benhammou (V)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.

Laetitia Marchand-Martin (L)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.

François Goffinet (F)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Department of Gynecology and Obstetrics, Port-Royal Hospital, APHP, Paris, France.

Pierre-Yves Ancel (PY)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Center for Clinical Investigation P1419, APHP, APHP Centre-Université Paris Cité, Paris, France.

Laurence Foix-L'Hélias (L)

Université Paris Cité, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, Université Paris Cité, Paris, France.
Department of Neonatal Pediatrics, Trousseau Hospital, APHP, Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH